Allogene Therapeutics Inc (ALLO)

Apr 25, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59% - Yahoo Finance

Apr 25, 2025

Apr 23, 2025

Allogene Therapeutics (ALLO) to Present New Findings on ALLO-316 and ALPHA3 Trials | ALLO Stock News - GuruFocus

Apr 23, 2025

Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncol - GuruFocus

Apr 23, 2025

Apr 23, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times

Apr 23, 2025

Apr 23, 2025

Allogene Therapeutics to Present Updated Data on ALLO-316 and ALPHA3 Trials at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025

Apr 23, 2025

First Allogeneic CAR T Shows Promise in Solid Tumors: Latest Clinical Data from Dual Cancer Trials at ASCO - Stock Titan

Apr 23, 2025

Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025

Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025

Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025

Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025

Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025

Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025

Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com India

Mar 19, 2025

Mar 18, 2025

Allogene Therapeutics CEO sells $91,469 in stock - Investing.com

Mar 18, 2025

Mar 18, 2025

Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Mar 18, 2025

Mar 18, 2025

Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com

Mar 18, 2025

Mar 17, 2025

7th Annual Allogeneic Cell Therapies Summit - pharmaphorum

Mar 17, 2025

Mar 17, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025

Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025

Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025

Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025

Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025

Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025

Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada

Mar 14, 2025

Mar 14, 2025

Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq

Mar 14, 2025

Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo

Mar 14, 2025

Mar 14, 2025

Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Mar 14, 2025

Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha

Mar 14, 2025

Mar 14, 2025

Citi maintains Buy on Allogene stock with $8 price target - Investing.com India

Mar 14, 2025